<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02341534</url>
  </required_header>
  <id_info>
    <org_study_id>HS058</org_study_id>
    <secondary_id>Preserved Ejection Fraction</secondary_id>
    <secondary_id>Implantable Cardiac Device</secondary_id>
    <secondary_id>Loop Recorder</secondary_id>
    <secondary_id>ICM</secondary_id>
    <nct_id>NCT02341534</nct_id>
  </id_info>
  <brief_title>BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Acute Myocardial Infarction</brief_title>
  <acronym>BIO|GUARD-MI</acronym>
  <official_title>BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BIO|GUARD-MI study investigates whether continuous arrhythmia monitoring and the
      consequent treatment after detected arrhythmias in patients after acute myocardial infarction
      with preserved cardiac function, but other risk factors, decreases the risk of major adverse
      cardiac events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients randomized to the BioMonitor arm will receive an implantable cardiac monitor (ICM;
      BioMonitor) with remote monitoring function (Home Monitoring®). If the device detects and
      reports an arrhythmia, patients will be appropriately examined and treated. Patients
      randomized to the control arm will receive best proven treatment, but no implantable cardiac
      monitor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first major cardiac adverse event (MACE)</measure>
    <time_frame>From randomization until official study end or drop-out, patients will be followed and assessed for primary endpoint events and Time-to-Event Outcome Measures for an expected average of 4.0 years.</time_frame>
    <description>MACE is defined as death for cardiovascular reasons or unplanned hospitalization for cardiovascular reasons as per study protocol.
The time period with regards to the Time-to-Event Outcome Measures starts with the randomization of the patient.
All patients will be assessed for Time-to-Event Outcome Measures until formal study termination is announced or until the individual patient meets a drop out criterion in accordance with the study protocol. The study period is estimated 6 years.
From randomization until official study end or drop-out, patients will be followed and assessed for primary endpoint events and Time-to-Event Outcome Measures for an expected average of 4.0 years.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2900</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>BioMonitor arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BioMonitor group (standard of care and implantation with investigational device)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group (standard of care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioMonitor</intervention_name>
    <description>Patients will be implanted with the BioMonitor + standard of care</description>
    <arm_group_label>BioMonitor arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of AMI according to guidelines

          -  CHA2DS2-VASc-Score ≥ 4 in men / ≥ 5 in women

          -  LVEF &gt; 35 % as estimated within 6 months before enrollment but after conclusion of AMI
             treatment

          -  Patient accepts activation of Home Monitoring®

          -  Patient has provided written informed consent

        Exclusion Criteria:

          -  Platelet count &lt; 90.000 per mm3 or patients with haemorrhagic diathesis

          -  Permanent oral anticoagulation treatment for atrial fibrillation

          -  Indication for chronic renal dialysis

          -  Pacemaker or ICD implanted or indication for implantation

          -  Parkinson's disease

          -  Life expectancy &lt; 1 year

          -  Participation in another interventional clinical Investigation

          -  Age &lt; 18 years

          -  Woman who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Jons, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet; Denmark; Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Behrens, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vivantes Humboldt Klinikum, Germany, Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Poul Erik Bloch Thomsen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Aalborg University Hospital, Denmark, Aalborg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Sogaard, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital, Denmark, Aalborg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sascha Mrosk</last_name>
    <phone>+49 (0) 30 68905-1308</phone>
    <email>bio-guard-mi@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maike Kluding</last_name>
    <phone>+49 (0) 30 68905-1371</phone>
    <email>bio-guard-mi@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg Universitetshospitel</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Sogaard, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens Cosedis Nielsen, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Karl Jacobsen, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Herning</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerzy Malczynski, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitets Hospital Roskilde</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Melchior, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Viborg</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Dahl Christensen, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Humboldt-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13509</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Behrens, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Brachmann, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Jung, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

